Table 2.
Comparison of treatment groups at baseline
| Osurnia | Placebo | P-Value | ||
|---|---|---|---|---|
| Number | 190 | 94 | ||
| Age | (mean (range); yrs | 6.1 (0.3–16.4) | 6.1 (0.3–15.8) | 0.9097 |
| Body weight | < 40 lbs.; N (%) | 78 (41%) | 41 (44%) | 0.8617 |
| 40–79 lbs.; n (%) | 64 (34%) | 32 (34%) | ||
| ≥80 lbs.; n (%) | 48 (25%) | 21 (22%) | ||
| Gender | F:M ratio | 90:100 = 0.9 | 52:42 = 1.2 | 0.2564 |
| Ears affected | One ear; n (%) | 17 (9%) | 7 (7%) | 0.8217 |
| Two ears; n (%) | 173 (91%) | 87 (93%) | ||
| History of otitis | Acute; n (%) | 47 (25%) | 29 (31%) | 0.5436 |
| Subchronic; n (%) | 73 (38%) | 32 (34%) | ||
| Chronic; n (%) | 70 (37%) | 33 (35%) | ||
| Exudate Type | Erythematous/ceruminous; n (%) | 158 (83%) | 78 (83%) | 1.000 |
| Suppurative; n (%) | 32 (17%) | 16 (17%) | ||
| Frequency of Otitis | Recurrent otitis; n (%) | 22 (12%) | 9 (10%) | 0.6894 |
| Hearing Loss | Can hear at Day 0; n (%) | 181 (97%) | 90 (96%) | 0.4846 |